Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming oral presentation of complete safety and efficacy data on all patients from its Phase 1/2 multidose study of VGA039 for von Willebrand disease (VWD), along with additional presentations on the program, at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress), being held July 11-15, 2026, in Paris, France.
VGA039 is an investigational monoclonal antibody therapy designed to modulate Protein S to improve hemostasis and improve the body’s ability to control bleeding. VGA039 is in Phase 3 pivotal development for patients with VWD, the most common inherited bleeding disorder. It has the potential to be the first subcutaneous prophylactic therapy for all types of VWD with a once monthly dosing regimen for patients.
Earlier this month, Incyte (Nasdaq:INCY) announced it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion upfront, subject to customary closing adjustments. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 billion. The proposed acquisition would add VGA039 to Incyte’s hematology portfolio.
